Simvastatin monotherapy as a potential option for statin-associated muscle symptoms: a case report

J Clin Pharm Ther. 2016 Oct;41(5):568-71. doi: 10.1111/jcpt.12419. Epub 2016 Jul 18.

Abstract

What is known and objectives: Choosing an alternative statin is recommended when managing statin-associated muscle symptoms (SAMS) and new hydrophilic statins are often suggested. We report on a case of statin-associated muscle damage that was successfully managed by simplifying the patient's combination therapy with simvastatin-ezetimibe to simvastatin alone.

Case summary: The patient experienced SAMS when he was successively treated with atorvastatin, rosuvastatin, Xuezhikang capsule and combined simvastatin/ezetimibe therapy. However, the patient tolerated simvastatin therapy well even at a dose of 40 mg/day.

What is new and conclusion: Our case suggests that patients with SAMS who are intolerant to a wide variety of statins may be successfully managed with simvastatin monotherapy.

Keywords: alternative statin; simvastatin; statin-associated muscle symptoms.

Publication types

  • Case Reports

MeSH terms

  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
  • Male
  • Middle Aged
  • Muscular Diseases / chemically induced*
  • Simvastatin / adverse effects*

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Simvastatin